ADC Therapeutics’ Lotis-5 confirmatory study continued to reverberate after safety signals complicated the company’s path to full DLBCL approval. Data showed no overall survival benefit and a higher number of treatment-arm deaths compared with control, amplifying concerns among investors and clinicians about the regimen’s benefit-risk profile. In lymphoma-adjacent coverage, separate oncology pipeline updates also highlighted how trial endpoints and safety signals are increasingly shaping corporate strategy around registrational execution. For stakeholders, the key question is whether the safety profile and interpretability of death signals will weigh into regulators’ decisions and uptake in second-line practice.